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Introduction
Chronic ITP is an autoimmune disorder manifested by
immune-mediated platelet destruction and suppressed
platelet production. The following article will discuss:
normal platelet production and circulation; ITP patho-
physiology; and diagnosis and treatment options for ITP.
Platelet production and circulation
Thrombopoietin (TPO), the major cytokine affecting all
phases of platelet production, is produced primarily by
the liver and binds to the c-Mpl receptor located on plate-
lets, stem cells and megakaryocytes. Upon stimulation,
pluripotential stem cells produce cells committed to meg-
akaryocyte differentiation. These cells initially undergo
mitosis followed eventually by endomitosis resulting in a
progressive increase in size with cells ranging from 2N to
64N and a proportional cytoplasmic increase. Platelet for-
mation occurs in the cytoplasm and the number of plate-
lets produced/megakaryocyte is roughly proportional to
megakaryocyte size. Platelet production is regulated as fol-
lows: the liver produces a constant quantity of TPO each
day and a large portion of this binds to circulating plate-
lets; unbound TPO is available to stimulate platelet pro-
duction. In thrombocytopenic states due to reduced
platelet production, less TPO is adsorbed by circulating
platelets and more is available to stimulate platelet pro-
duction. In ITP, TPO levels are normal or slightly
increased probably due to TPO binding to platelets which
are then destroyed, removing TPO from the circulation.
Circulating platelets have an intravascular survival of 7–
10 days. About 30% are located in an exchangeable
splenic pool which, if enlarged, may result in peripheral
thrombocytopenia (e.g., patients with congestive
splenomegaly). Platelets are removed from the circulation
due to utilization in maintaining vascular integrity or
because of old age.
Differential diagnosis of thrombocytopenia
Thrombocytopenia can result from: decreased platelet
production, platelet redistribution (enlarged splenic
pool) or platelet destruction. Decreased production may
be due to myeloproliferative disorders (leukemia, mye-
loma, etc.), myelodysplasia, aplasia or hypoplasia, drugs
(chemotherapy, alcohol, etc.), malignant infiltration or
may be inherited. Decreased production is usually diag-
nosed by evaluation of the blood count and bone mar-
row. Abnormal platelet distribution involves an enlarged
spleen and is most commonly due to congestive splenom-
egaly although other disorders such as lymphoma, Gau-
cher's disease, etc. may also have some element of
redistribution. There are multiple causes of platelet
destruction including infection, thrombotic thrombocy-
topenic purpura, disseminated intravascular coagulation
or immune causes due to alloantibodies, drug-dependent
antibodies, acute ITP or chronic ITP or ITP-like syndromes
associated with collagen vascular or lymphoproliferative
disorders.
Chronic ITP is a diagnosis of exclusion. The classic ITP
patient presents with petechiae and easy bruising with or
without mucosal bleeding. The blood count shows only
isolated thrombocytopenia with scattered large platelets.
Anemia is absent, unless there is bleeding or immune
hemolysis. The bone marrow is normal except for an
increase in megakaryocytes.
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Thrombocytopenia in ITP may be due to platelet destruc-
tion, suppressed platelet production or both. Evidence for
platelet destruction: (1) infusion of ITP plasma into nor-
mal recipients may cause thrombocytopenia; (2) intravas-
cular platelet survival is reduced; (3) autoantibody-
induced platelet phagocytosis can be demonstrated and
(4) ITP cytotoxic T cells can lyse autologous platelets and
(5) many patients respond to therapies which affect plate-
let destruction, such as splenectomy, intravenous gamma-
globulin (IVIg), anti-D, etc. Evidence for suppressed
platelet production: (1) platelet turnover (a measure of
platelet production) is either normal or reduced in over
80% of ITP patients rather than increased as would be
expected if platelet destruction were the only mechanism;
(2) damage to ITP megakaryocytes can be demonstrated
morphologically; (3) autoantibody from some ITP
patients suppresses platelet production and maturation in
vitro; and (4) the majority of patients respond to TPO
mimetics which stimulate platelet production. It is likely
that ITP cytotoxic T cells also damage megakaryocytes,
since they have similar surface proteins, but this has not
been confirmed.
Thrombopoietin mimetics: a new therapeutic 
approach
A few years ago, thrombopoietin and agents, containing
the active portion of thrombopoietin, were developed and
used to treat ITP patients. However, their use was discon-
tinued when antibodies against these agents developed
which rendered them inactive and, in addition, affected
the function of the recipient's normal thrombopoietin.
Subsequently, a variety of agents have been developed,
including small peptide or non-peptide molecules, which
have no sequence homology with TPO but are able to
stimulate platelet production. Two of these agents, romi-
plostim (NPlate®) and eltrombopag (Promacta®) have
undergone clinical trials and recently received FDA
approval for use in chronic ITP.
Based on these clinical trials, it has been shown that both
agents increase the platelet count in most chronic ITP
patients most of the time resulting in reduced bleeding
and allowing many patients to reduce or stop other ITP
therapies. Although adverse events have been infrequent,
there are potentially serious adverse events which may
occur with long-term use of these agents: (1) severe
thrombocytopenia upon stopping the drug with platelet
counts significantly below pre-treatment levels for up to
two weeks requiring, in some cases, rescue therapy; (2)
increased bone marrow reticulum which thus far has been
reversible in the few patients studied; (3) possible stimu-
lation of leukemic cell growth (11 of 44 patients with
myelodysplasia, receiving romiplostim, developed dis-
ease progression, four progressing to acute granulocytic
leukemia); (4) hepatobiliary toxicity (eltrombopag).
Potentially serious adverse events which have not been
seen thus far include: thrombosis/thromboembolism,
antibody formation against the drug and stem cell deple-
tion.
Therapy of chronic ITP
Emergency therapy
Emergency therapy should be considered if the platelet
count is <5000 per l or if there is significant mucosal or
CNS bleeding. Hospitalization may be indicated. Patients
should receive intravenous gammaglobulin (IVIG) 1.0 g/
kg/d IV for two days and/or methylprednisolone 1.0 g/d
IV for 3 days. Platelet transfusion may be indicated to con-
trol bleeding.
First-line therapy
A percentage of ITP patients will attain a spontaneous par-
tial or complete remission if their platelet count can be
maintained until this occurs. The purpose of first-line
therapy is to maintain a safe platelet count (> 25–30,000
per ul) to either provide time for spontaneous recovery or
to give therapy which will reverse the abnormal immune
response. If no response occurs after therapy for several
weeks or if patients relapse after a response, second line
therapy should be given. The following therapies should
be considered: (1) prednisone – 1 mg/kg daily p.o. until a
response occurs followed by tapering over a period of sev-
eral weeks; (2) high-dose dexamethasone – 40 mg PO or
IV/d × 4 every 14 days × 4; (3) Anti-D – 50–75 ug/kg IV
prn to maintain the platelet count >30,000 per ul; (4)
rituximab – 375 mg/M2 IV per week × 4; or (5) throm-
bopoietin mimetics – romiplostim (1–10 ug/kg s.c.
weekly) or eltrombopag (25–75 mg po daily on an empty
stomach) aiming to maintain a platelet count of  50,000
per ul.
Second line therapy
If there is continued, symptomatic thrombocytopenia
after therapeutic trials of the above agents, there are two
possible considerations: (1) splenectomy or (2) continue
the thrombopoietin mimetic, if the patient continues to
respond. Splenectomy would seem to be the wiser choice
at this time since long-term results are not yet available for
the thrombopoietin mimetics.
Splenectomy has been used for chronic ITP for over 50
years and there are solid long-term data showing that
about two thirds of patients are cured of their disease.
Immunizations for pneumococcus, meningococcus and
H. influenza should be given and, if possible, the platelet
count should be raised above 50,000 per ul pre-op using
corticosteroids, IVIG or anti-D. Platelets should be availa-
ble but not given unless excessive bleeding occurs. Lapar-
oscopic splenectomy is recommended since results arePage 2 of 3
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equal to standard splenectomy and patients recover more
rapidly and require shorter hospitalizations.
Therapy of refractory ITP
For patients failing splenectomy, several options are avail-
able. A retrial of prednisone ± dapsone or danazol, rituxi-
mab or one of the TPO mimetics should be considered.
Patients, who do not respond, can be treated with chemo-
therapeutic agents (azathioprine or oral cyclophospha-
mide) or immunosuppressants (cyclosporine or
mycophenolate mofetil). In patients, who remain throm-
bocytopenic and have symptomatic bleeding, considera-
tion may be given to more toxic therapy such as high-dose
cyclophosphamide, combination chemotherapy or stem
cell transplantation.Page 3 of 3
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